2,4-dichloro-6-(3,4-dimethoxy)phenylpyrimidine | 371171-21-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,4-dichloro-6-(3,4-dimethoxy)phenylpyrimidine
• 英文别名: 2,4-Dichloro-6-(3,4-dimethoxyphenyl)pyrimidine
• CAS: 371171-21-0
• 化学式: C₁₂H₁₀Cl₂N₂O₂
• mdl: MFCD21051140
• 分子量: 285.13
• InChiKey: CPSZRXXAPAXFEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  44.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,4-dichloro-6-(3,4-dimethoxy)phenylpyrimidine 在 bis-triphenylphosphine-palladium(II) chloride 、 三苯基膦 、 copper(I) bromide 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 6.5h， 生成 2-{(E)-2-[4-(1-imidazolyl)-quinazolin-2-yl]}ethenyl-4-(3,4-dimethoxy)phenyl-6-(pyrrolidin-1-yl)pyrimidine
  参考文献：
  名称：

  Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor

  摘要：

  本发明涉及一种通过给予具有磷酸二酯酶10抑制活性的化合物的有效量来治疗帕金森病的治疗或预防方法；还涉及一种用作治疗或预防帕金森病的药物组合物，其包括作为活性成分具有磷酸二酯酶10抑制活性的化合物。此外，本发明涉及一种增强大脑中多巴胺信号的方法，包括给予具有磷酸二酯酶10抑制活性的化合物的有效量；还涉及用作增强大脑中多巴胺信号的药物组合物，其包括作为活性成分具有磷酸二酯酶10抑制活性的化合物。

  公开号：

  US08338420B1
• 作为产物：
  描述：

  2,4,6-三氯嘧啶 、 3,4-dimethoxyphenylborate 在 bis-triphenylphosphine-palladium(II) chloride sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 1.67h， 以45%的产率得到2,4-dichloro-6-(3,4-dimethoxy)phenylpyrimidine
  参考文献：
  名称：

  Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor

  摘要：

  本发明涉及一种通过给予具有磷酸二酯酶10抑制活性的化合物的有效量来治疗帕金森病的治疗或预防方法；还涉及一种用作治疗或预防帕金森病的药物组合物，其包括作为活性成分具有磷酸二酯酶10抑制活性的化合物。此外，本发明涉及一种增强大脑中多巴胺信号的方法，包括给予具有磷酸二酯酶10抑制活性的化合物的有效量；还涉及用作增强大脑中多巴胺信号的药物组合物，其包括作为活性成分具有磷酸二酯酶10抑制活性的化合物。

  公开号：

  US08338420B1

文献信息

• Imidazopyrimidine derivatives and triazolopyrimidine derivatives
  申请人：——

  公开号：US20040054179A1

  公开（公告）日：2004-03-18

  A compound of the formula (I) wherein R 1 is —X—R 4 , an optionally substituted heterocyclic residue, an optionally substituted carbocyclic residue or optionally substituted condensed ring moiety; X is CR 5 R 6 , O, S, SO, SO 2 or NR 7 ; Y is CH or N; R 2 is H, an optionally substituted C 1 -C 10 alkyl,etc.; R 3 is an optionally substituted aryl, or an optionally substituted heteroaryl, etc.; R 4 is an optionally substituted aryl, an optionally substituted heteroaryl, etc.; R 5 , R 6 , and R 7 can be identical or different and represent H, an optionally substituted C 1 -C 10 alkyl, etc. The compound has an excellent anti-allergic activity and the like. 1

  化合物的结构式（I），其中R1是—X—R4，可选择取代的杂环残基，可选择取代的碳环残基或可选择取代的紧缩环基；X是CR5R6，O，S，SO，SO2或NR7；Y是CH或N；R2是H，可选择取代的C1-C10烷基等；R3是可选择取代的芳基，或可选择取代的杂芳基等；R4是可选择取代的芳基，可选择取代的杂芳基等；R5、R6和R7可以相同也可以不同，代表H，可选择取代的C1-C10烷基等。该化合物具有出色的抗过敏活性等。
• [EN] AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS CYCLIQUES AROMATIQUES AZOTÉS À 6 CHAÎNONS ET LEUR UTILISATION
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2010030027A1

  公开（公告）日：2010-03-18

  The present invention provides aromatic nitrogen-containing 6-membered ring compounds having execellent PDE10 inhibitory activity. The present invention relates to an aromatic nitrogen-containing 6-membered ring compound represented by the following formula [I0] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compounds for PDE10 inhibitors, and a pharmaceutical composition comprising said compounds as an active ingredient: Formula [I0] wherein: X1, X2 and X3 each independently are N or CH, and at least two of X1, X2 and X3 are N; A is *-CH=CH-, *-C(Alk)=CH-, *-CH2-CH2- or *-O-CH2- (* is a bond with R1); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R1 is an optionally substituted nitrogen-containing heterocyclic group, a nitrogen-containing heterocyclic moiety of which is a moiety selected from the group consisting of quinoxalinyl, quinolyl, isoquinolyl, quinazolinyl, pyrazinyl, pyrimidinyl and a moiety thereof fused with a 5 to 6-membered aliphatic ring thereto; Y0 is a group selected from the group consisting of the following (1) to (5): (1) an optionally substituted phenyl or an optionally substituted aromatic monocyclic 5 to 6-membered heterocyclic group; (2) an optionally substituted aminocarbonyl; (3) an optionally substituted amino lower alkyl; (4) -O-R2 wherein R2 is hydrogen, an optionally substituted lower alkyl, lower cycloalkyl, aliphatic monocyclic 5 to 6-membered heterocyclic group, or Formula [AA]; (5) mono- or di-substituted amino; provided that, when Y0 is mono- or di-substituted amino, the nitrogen-containing heterocyclic moiety of R1 is not quinoxalinyl or quinolyl.

  本发明提供了具有出色的PDE10抑制活性的芳香氮含6元环化合物。本发明涉及以下式[I0]所代表的芳香氮含6元环化合物或其药学上可接受的盐，其制备方法，以及将所述化合物用作PDE10抑制剂，以及包含所述化合物作为活性成分的药物组合物：式[I0]其中：X1、X2和X3各自独立地为N或CH，并且至少两个X1、X2和X3为N；A为*-CH=CH-，*-C(Alk)=CH-，*-CH2- -或*-O- -（*为与R1的键）；Alk为低碳烷基基团；环B为可选择取代的含氮脂肪杂环基团；R1为可选择取代的含氮杂环基团，其中的氮杂环基团为从喹喔啉基，喹啉基，异喹啉基，喹唑啉基，吡嗪基，嘧啶基中选取的基团，或者与其中的5至6元脂环融合的基团；Y0为从以下（1）到（5）组成的基团：（1）可选择取代的苯基或可选择取代的芳香单环5至6元杂环基团；（2）可选择取代的氨基羰基；（3）可选择取代的氨基低碳烷基；（4）-O-R2其中R2为氢，可选择取代的低碳烷基，低环烷基，脂肪单环5至6元杂环基团，或式[AA]；（5）单取代或双取代氨基；但是，当Y0为单取代或双取代氨基时，R1的含氮杂环基团不是喹喔啉基或喹啉基。
• AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE
  申请人：Morimoto Hiroshi

  公开号：US20110166135A1

  公开（公告）日：2011-07-07

  The present invention provides aromatic nitrogen-containing 6-membered ring compounds having excellent PDE10 inhibitory activity. The present invention relates to an aromatic nitrogen-containing 6-membered ring compound represented by the following formula [I 0 ] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compounds for PDE10 inhibitors, and a pharmaceutical composition comprising said compounds as an active ingredient: Formula [I 0 ] wherein: X 1 , X 2 and X 3 each independently are N or CH, and at least two of X 1 , X 2 and X 3 are N; A is *—CH═CH—, *—C(Alk)=CH—, *—CH 2 —CH 2 — or *—O—CH 2 — (* is a bond with R 1 ); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R 1 is an optionally substituted nitrogen-containing heterocyclic group, a nitrogen-containing heterocyclic moiety of which is a moiety selected from the group consisting of quinoxalinyl, quinolyl, isoquinolyl, quinazolinyl, pyrazinyl, pyrimidinyl and a moiety thereof fused with a 5 to 6-membered aliphatic ring thereto; Y 0 is a group selected from the group consisting of the following (1) to (5): (1) an optionally substituted phenyl or an optionally substituted aromatic monocyclic 5 to 6-membered heterocyclic group; (2) an optionally substituted aminocarbonyl; (3) an optionally substituted amino lower alkyl; (4) —O—R 2 wherein R 2 is hydrogen, an optionally substituted lower alkyl, lower cycloalkyl, aliphatic monocyclic 5 to 6-membered heterocyclic group, or Formula [AA]; (5) mono- or di-substituted amino; provided that, when Y 0 is mono- or di-substituted amino, the nitrogen-containing heterocyclic moiety of R 1 is not quinoxalinyl or quinolyl.

  本发明提供了具有优异的PDE10抑制活性的芳香族含氮6元环化合物。本发明涉及以下式[I0]或其药学上可接受的盐，其为一种芳香族含氮6元环化合物，以及其制备方法，用于PDE10抑制剂的化合物和包含该化合物作为活性成分的药物组合物：式[I0]其中：X1、X2和X3各自独立地为N或CH，且至少两个X1、X2和X3为N；A为*—CH═CH—、*—C(Alk)=CH—、*—CH2— —或*—O— —（*为R1的键）；Alk为低碳基；环B为可选取代的含氮脂肪族杂环基；R1为可选取代的含氮杂环基，其中含氮杂环基是从喹啉基、喹啉基、异喹啉基、喹唑啉基、吡嗪基、嘧啶基和它们与5至6元脂环环融合的基中选择的基；Y0为从以下组合中选择的基（1）到（5）：（1）可选取代的苯基或可选取代的芳香单环5至6元杂环基；（2）可选取代的氨基甲酰基；（3）可选取代的氨基低碳基；（4）—O—R2，其中R2为氢、可选取代的低碳基、低环烷基、脂肪单环5至6元杂环基或式[AA]；（5）单取代或双取代的氨基；但当Y0为单取代或双取代的氨基时，R1的含氮杂环基不是喹啉基或喹啉基。
• TREATMENT OF PARKINSON'S DISEASE AND ENHANCEMENT OF DOPAMINE SIGNAL USING PDE 10 INHIBITOR
  申请人：MITSUBISHI TANABE PHARMA COPORATION

  公开号：US20130072477A1

  公开（公告）日：2013-03-21

  The present invention relates to a therapeutic or prophylactic method for treating Parkinson's disease by administering an effective amount of a compound having a phosphodiesterase 10 inhibitory activity; and also relates to a pharmaceutical composition for treatment or prophylaxis of Parkinson's disease comprising as an active ingredient a compound having a phosphodiesterase 10 inhibitory activity. Moreover, the present invention relates to a method for enhancing dopamine signal in the brain, which comprises administering an effective amount of a compound having a phosphodiesterase 10 inhibitory activity; and also relates to pharmaceutical composition for enhancing dopamine signal in brain comprising as an active ingredient a compound having a phosphodiesterase 10 inhibitory activity.

  本发明涉及一种治疗或预防帕金森病的方法，该方法通过给予具有磷酸二酯酶10抑制活性的化合物的有效量来实现；还涉及一种用于治疗或预防帕金森病的药物组合物，其中包括作为活性成分的具有磷酸二酯酶10抑制活性的化合物。此外，本发明还涉及一种增强大脑中多巴胺信号的方法，该方法包括给予具有磷酸二酯酶10抑制活性的化合物的有效量；还涉及一种增强大脑中多巴胺信号的药物组合物，其中包括作为活性成分的具有磷酸二酯酶10抑制活性的化合物。
• IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES
  申请人：Bayer HealthCare AG

  公开号：EP1278750B1

  公开（公告）日：2004-08-04